Lead Product(s): OATD-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: $380.8 million Upfront Cash: $29.7 million
Deal Type: Licensing Agreement November 05, 2020
OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.